Schwab Charles Investment Management Inc. grew its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 7.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 117,236 shares of the medical research company’s stock after purchasing an additional 7,930 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.23% of Accelerate Diagnostics worth $3,207,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of AXDX. Wells Fargo & Company MN lifted its holdings in shares of Accelerate Diagnostics by 47.2% in the first quarter. Wells Fargo & Company MN now owns 60,488 shares of the medical research company’s stock valued at $1,464,000 after purchasing an additional 19,388 shares in the last quarter. Stifel Financial Corp bought a new stake in shares of Accelerate Diagnostics in the first quarter valued at about $274,000. SG Americas Securities LLC lifted its holdings in shares of Accelerate Diagnostics by 16.8% in the first quarter. SG Americas Securities LLC now owns 5,885 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 846 shares in the last quarter. American International Group Inc. lifted its holdings in shares of Accelerate Diagnostics by 7.1% in the first quarter. American International Group Inc. now owns 14,187 shares of the medical research company’s stock valued at $343,000 after purchasing an additional 939 shares in the last quarter. Finally, FMR LLC bought a new stake in shares of Accelerate Diagnostics in the first quarter valued at about $7,260,000. Institutional investors own 44.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Raises Stake in Accelerate Diagnostics, Inc. (AXDX)” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/20/schwab-charles-investment-management-inc-raises-stake-in-accelerate-diagnostics-inc-axdx.html.

In related news, Director Jack W. Schuler purchased 59,922 shares of the business’s stock in a transaction on Monday, October 16th. The stock was acquired at an average price of $20.07 per share, for a total transaction of $1,202,634.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler purchased 61,300 shares of the business’s stock in a transaction on Friday, October 13th. The shares were bought at an average price of $19.29 per share, with a total value of $1,182,477.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 610,622 shares of company stock valued at $12,344,792 in the last quarter. Company insiders own 50.00% of the company’s stock.

A number of analysts have recently commented on the company. Zacks Investment Research lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Finally, BTIG Research restated a “buy” rating and issued a $34.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Three research analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $33.00.

Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) opened at 19.95 on Friday. Accelerate Diagnostics, Inc. has a 12-month low of $18.35 and a 12-month high of $30.45. The company’s market cap is $1.10 billion. The company’s 50-day moving average price is $22.21 and its 200 day moving average price is $25.36.

Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.40 million. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. Equities analysts predict that Accelerate Diagnostics, Inc. will post ($1.20) earnings per share for the current year.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.